A bold new plan by the FDA commissioner has sparked alarm and controversy, raising questions about the future of drug approvals.
The commissioner's initiative, aimed at drastically shortening the review process for certain drugs, has caused anxiety and confusion within the agency. This plan, favored by the Trump administration, threatens to undermine long-standing legal, ethical, and scientific standards that ensure the safety and effectiveness of new medicines.
Marty Makary's program has added to the turmoil already caused by layoffs, buyouts, and leadership changes, according to current and former FDA staffers. At the heart of the matter is the National Priority Voucher program, which promises approval in as little as one month for drugs supporting "U.S. national interests."
But here's where it gets controversial: traditionally, approval decisions have been made by FDA review scientists and their supervisors, not political appointees. Drug reviewers are concerned about the lack of information on the new program's workings, and some staffers working on an anti-obesity pill were even told to skip certain regulatory steps to meet aggressive deadlines.
Outside experts emphasize that FDA drug reviews are already the fastest in the world, ranging from six to ten months. Dr. Aaron Kesselheim, a professor at Harvard Medical School, states, "The concept of doing a review in one to two months just does not have scientific precedent."
Reuters reported that FDA officials have delayed the review of two drugs in the program due to safety concerns, including a patient's death while taking one of the medications.
The voucher program, which aims to deliver "meaningful and effective treatments and cures," has gained popularity at the White House. However, it has sparked widespread concern that FDA drug reviews, once objective, are now open to political interference.
"It's extraordinary to have such an opaque application process, one that is obviously susceptible to politicization," says Paul Kim, a former FDA attorney.
Top FDA officials have declined to sign off on expedited approvals, citing legal concerns. The program's lack of federal rules and regulations has left many questions unanswered.
The FDA already has several programs to speed up or streamline reviews for promising drugs, all approved by Congress. In contrast, the voucher program's information is mostly on an agency website, and drugmakers can apply with a simple 350-word statement.
Agency leaders, like Dr. Vinay Prasad, have been directly contacting drugmakers about awarding vouchers, creating confusion for FDA staffers. Questions about the program's legality led the former FDA drug director, Dr. George Tidmarsh, to decline to sign off on approvals.
After Tidmarsh's resignation, the responsibility fell to Dr. Mallika Mundkur, the agency's deputy chief medical officer. Giving final approval to a drug carries significant legal risks, and traditionally, approval comes from FDA drug office directors in consultation with reviewers.
Under the voucher program, approval comes through a committee vote led by senior agency leaders, a complete reversal from the normal review process.
Not everyone sees problems with the program. Dan Troy, the FDA's top lawyer under President George W. Bush, says federal law gives the commissioner discretion to reorganize drug reviews. However, he acknowledges that the voucher program may be short-lived due to its lack of codification.
The voucher program has expanded beyond its initial scope of five drugs, with 18 vouchers awarded and more under consideration. This puts extra pressure on the FDA's drug center, where staff turnover has been high.
When Makary unveiled the program, concerns arose about the unprecedented power he would hold in deciding which companies benefit. Initially, nominations for drugs came from career staffers, but selection decisions are now led by Prasad or other senior officials.
Access to Makary is limited due to his non-use of a government email account, breaking with precedent.
Some FDA reviewers, under pressure from drugmakers, were told they could skip steps in the review process. This approach, according to former reviewers and experts, is the opposite of how FDA reviews should work, as it undermines the scientific confirmation of drug safety and effectiveness.
Skipping review steps could also pose risks for drugmakers if future FDA leaders decide a drug wasn't properly vetted. Experts like Kesselheim believe the program may not outlast the current administration.
"They are fundamentally changing the application of the standards, but the underlying law remains," Kesselheim says. "The hope is that one day we will return to these scientifically and legally sound principles."
What are your thoughts on this controversial plan? Do you think it's a necessary step to expedite drug approvals, or does it compromise the integrity of the FDA's review process? Share your opinions in the comments below!
